 <h1>Gazyva Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>obinutuzumab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about obinutuzumab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Gazyva.</p><h2>In Summary</h2><p><b>Common side effects of Gazyva include:</b> infection, fever, hyperkalemia, hypocalcemia, hypokalemia, hypophosphatemia, and neutropenia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to obinutuzumab: intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Hepatitis B virus (HBV) reactivation can occur in patients receiving obinutuzumab or other CD20-directed cytolytic antibodies, which can progress to life-threatening or fatal fulminant hepatitis or hepatic failure. Screen patients at baseline for HBV infection. Monitor HBV-positive patients during and after treatment with obinutuzumab. If HBV reactivation occurs, discontinue obinutuzumab and concomitant medications. Life-threatening or fatal progressive multifocal leukoencephalopathy has also been reported.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, obinutuzumab (the active ingredient contained in Gazyva) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking obinutuzumab:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>chest tightness</li>
<li>chills</li>
<li>cough</li>
<li>fever</li>
<li>flushing</li>
<li>headache</li>
<li>hoarseness</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>sore throat</li>
<li>trouble breathing</li>
<li>troubled breathing with exertion</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Joint pain, stiffness, or swelling</li>
<li>stomach pain</li>
<li>swelling of the feet or lower legs</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blurred vision</li>
<li>confusion</li>
<li>dark urine</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>general tiredness and weakness</li>
<li>light-colored stools</li>
<li>seizures</li>
<li>upper right abdominal or stomach pain</li>
<li>yellow eyes and skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of obinutuzumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to obinutuzumab: intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, cardiac failure</p>
<p><b>Frequency not reported</b>: Worsening of preexisting cardiac conditions with fatalities, atrial fibrillation<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (41%), thrombocytopenia (15%), anemia (12%)</p>
<p><b>Common</b> (1% to 10%): Leukopenia, lymph node pain<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): AST (SGOT) increased (28%), ALT (SGPT) increased (25%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypophosphatemia (36%), hypoalbuminemia (33%), hypoproteinemia (32%), hypocalcemia (32%), hypocalcemia (32%), hyperuricemia (28%), hyponatremia (26%), hyperkalemia (23%), hypernatremia (16%) alkaline phosphatase increased (16%), decreased appetite (14%)</p>
<p><b>Common</b> (1% to 10%): Tumor lysis syndrome, hyperuricemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, back pain, musculoskeletal chest pain, pain in extremity, bone pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (18%), asthenia</p>
<p><b>Frequency not reported</b>: Progressive multifocal leukoencephalopathy (PML)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (18%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (30%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (26%), pneumonia (14%), sinusitis (12%), upper respiratory tract infection</p>
<p><b>Common</b> (1% to 10%): Rhinitis, pharyngitis, nasopharyngitis, lung infection, nasal congestion, rhinorrhea, lung infection<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Positive test for anti-obinutuzumab (the active ingredient contained in Gazyva) antibodies (13%)</p>
<p><b>Common</b> (1% to 10%): Infection (9%)</p>
<p><b>Frequency not reported</b>: Hepatitis B reactivation, immunogenicity<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (13%)</p>
<p><b>Common</b> (1% to 10%): Pruritus, night sweats, eczema<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion related reactions (69%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Ocular hyperemia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, urinary incontinence, dysuria<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Squamous cell carcinoma of the skin<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (19%), diarrhea (10%)</p>
<p><b>Common</b> (1% to 10%): Oral herpes, dyspepsia, colitis, hemorrhoids<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: This drug can cause serious infusion reactions.  See Warnings.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Gazyva (obinutuzumab)." Genentech, South San Francisco, CA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is Gazyva used for and how does it work?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Gazyva (obinutuzumab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: CD20 monoclonal antibodies</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Gazyva &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Lymphocytic Leukemia</li>
<li>Follicular Lymphoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to obinutuzumab: intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, cardiac failure</p><p><b>Frequency not reported</b>: Worsening of preexisting cardiac conditions with fatalities, atrial fibrillation<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (41%), thrombocytopenia (15%), anemia (12%)</p><p><b>Common</b> (1% to 10%): Leukopenia, lymph node pain<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): AST (SGOT) increased (28%), ALT (SGPT) increased (25%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypophosphatemia (36%), hypoalbuminemia (33%), hypoproteinemia (32%), hypocalcemia (32%), hypocalcemia (32%), hyperuricemia (28%), hyponatremia (26%), hyperkalemia (23%), hypernatremia (16%) alkaline phosphatase increased (16%), decreased appetite (14%)</p><p><b>Common</b> (1% to 10%): Tumor lysis syndrome, hyperuricemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, back pain, musculoskeletal chest pain, pain in extremity, bone pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (18%), asthenia</p><p><b>Frequency not reported</b>: Progressive multifocal leukoencephalopathy (PML)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (18%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (30%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (26%), pneumonia (14%), sinusitis (12%), upper respiratory tract infection</p><p><b>Common</b> (1% to 10%): Rhinitis, pharyngitis, nasopharyngitis, lung infection, nasal congestion, rhinorrhea, lung infection<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Positive test for anti-obinutuzumab (the active ingredient contained in Gazyva) antibodies (13%)</p><p><b>Common</b> (1% to 10%): Infection (9%)</p><p><b>Frequency not reported</b>: Hepatitis B reactivation, immunogenicity<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (13%)</p><p><b>Common</b> (1% to 10%): Pruritus, night sweats, eczema<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion related reactions (69%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Ocular hyperemia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, urinary incontinence, dysuria<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Squamous cell carcinoma of the skin<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (19%), diarrhea (10%)</p><p><b>Common</b> (1% to 10%): Oral herpes, dyspepsia, colitis, hemorrhoids<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: This drug can cause serious infusion reactions.  See Warnings.<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Gazyva (obinutuzumab)." Genentech, South San Francisco, CA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is Gazyva used for and how does it work?</li>
</ul><h2>More about Gazyva (obinutuzumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: CD20 monoclonal antibodies</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Gazyva &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Lymphocytic Leukemia</li>
<li>Follicular Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>